Novartis looks set to buy US-based The Medicines Company in a US$9 billion deal that will see the Swiss company acquire rights to the world's first RNAi therapeutic for lowering cholesterol.

Latest Video
New Stories
-
Clinical trials: Competition across countries and companies
December 13, 2019 - - Latest News -
High in fees low on performance measures
December 13, 2019 - - Latest News -
Deborah Monk: Recollections from APMA to Medicines Australia
December 13, 2019 - - Latest News -
Novartis launches Innovation Prize with a focus on MS
December 13, 2019 - - Latest News -
New leadership for AbbVie Australia
December 12, 2019 - - Latest News -
Key trade agreement scraps pharma IP provision
December 12, 2019 - - Latest News -
Still time to take advantage of BioPharmaDispatch 2020 early registration
December 12, 2019 - - Latest News